|
Study
|
Genotype
|
Cases (percentage)
|
Controls (percentage)
|
OR (95% CI)a
|
|---|
|
NHS1
|
T/T
|
541 (43.3)
|
699 (40.6)
|
1.00 (reference)
|
| |
T/C
|
567 (45.4)
|
808 (47.0)
|
0.89 (0.75–1.04)
|
| |
C/C
|
141 (11.3)
|
213 (12.4)
|
0.80 (0.62–1.03)
|
| | | | |
p trend = 0.05
|
|
NHS2
|
T/T
|
140 (46.5)
|
270 (44.3)
|
1.00 (reference)
|
| |
T/C
|
131 (43.5)
|
259 (42.5)
|
0.97 (0.72–1.31)
|
| |
C/C
|
30 (10.0)
|
81 (13.3)
|
0.72 (0.45–1.15)
|
| | | | |
p trend = 0.26
|
|
WHS
|
T/T
|
281 (43.6)
|
278 (42.7)
|
1.00 (reference)
|
| |
T/C
|
296 (46.0)
|
294 (45.2)
|
0.99 (0.78–1.26)
|
| |
C/C
|
67 (10.4)
|
79 (12.1)
|
0.86 (0.58–1.25)
|
| | | | |
p trend = 0.53
|
|
Pooled
|
T/T
|
962 (43.8)
|
1,246 (41.8)
|
1.00 (reference)
|
| |
T/C
|
994 (45.3)
|
1,361 (45.7)
|
0.93 (0.82–1.05)
|
| |
C/C
|
238 (10.8)
|
373 (12.5)
|
0.80 (0.66–0.97)
|
| | | | |
p trend = 0.02
|
-
aUnconditional logistic regression controlled for age, age at first birth and parity, menopausal status at diagnosis, history of benign breast disease, and family history of breast cancer. CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; PTGS2, prostaglandin endoperoxide synthase 2; WHS, Harvard Women's Health Study.
